TWA
VRTX icon

TCI Wealth Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

TCI Wealth Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-183
Closed -$57.7K – 2191
2023
Q1 		$57.7K Buy
183
+4
+2% +$1.2K 0.01% 398
2022
Q4 		$51.7K Buy
179
+33
+23% +$10.1K 0.01% 402
2022
Q3 		$42K Buy
146
+21
+17% +$6.04K 0.01% 417
2022
Q2 		$35K Hold
125
– – 0.01% 470
2022
Q1 		$33K Buy
125
+2
+2% +$475 ﹤0.01% 517
2021
Q4 		$27K Buy
123
+39
+46% +$7.58K ﹤0.01% 581
2021
Q3 		$15K Buy
84
+19
+29% +$3.71K ﹤0.01% 842
2021
Q2 		$13K Sell
65
-69
-51% -$14.4K ﹤0.01% 822
2021
Q1 		$29K Buy
134
+124
+1,240% +$27.2K 0.01% 490
2020
Q4 		$2K Hold
10
– – ﹤0.01% 1290
2020
Q3 		$3K Hold
10
– – ﹤0.01% 1025
2020
Q2 		$3K Hold
10
– – ﹤0.01% 978
2020
Q1 		$2K Sell
10
-30
-75% -$6.88K ﹤0.01% 1118
2019
Q4 		$9K Buy
40
+10
+33% +$2.02K ﹤0.01% 736
2019
Q3 		$5K Hold
30
– – ﹤0.01% 831
2019
Q2 		$6K Hold
30
– – ﹤0.01% 742
2019
Q1 		$6K Hold
30
– – ﹤0.01% 759
2018
Q4 		$5K Hold
30
– – ﹤0.01% 787
2018
Q3 		$6K Hold
30
– – ﹤0.01% 766
2018
Q2 		$5K Buy
30
+20
+200% +$3.1K ﹤0.01% 791
2018
Q1 		$2K Hold
10
– – ﹤0.01% 1027
2017
Q4 		$1K Hold
10
– – ﹤0.01% 1279
2017
Q3 		$2K Hold
10
– – ﹤0.01% 1008
2017
Q2 		$1K Hold
10
– – ﹤0.01% 1231
2017
Q1 		$1K Hold
10
– – ﹤0.01% 1180
2016
Q4 		$1K Sell
10
-38
-79% -$3.09K ﹤0.01% 1248
2016
Q3 		$4K Buy
48
+27
+129% +$2.55K ﹤0.01% 814
2016
Q2 		$2K Sell
21
-3
-13% -$259 ﹤0.01% 972
2016
Q1 		$2K Buy
+24
New +$2.17K ﹤0.01% 982
2015
Q4 		– Sell
-18
Closed -$2K – 1090
2015
Q3 		$2K Buy
+18
New +$2.31K ﹤0.01% 824

Other funds holding VRTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

TCI Wealth Advisors's VRTX Position: Q2 2023 in Review

TCI Wealth Advisors sold out of Vertex Pharmaceuticals (VRTX) in Q2 2023, closing a stake of 183 shares — an estimated $57.7K sold.

TCI Wealth Advisors first reported a position in VRTX in Q3 2015 and held it in 30 quarters. The position peaked at $57.7K in Q1 2023. 1,286 funds tracked by Wall St. Rank hold VRTX as of Q2 2023.

  • TCI Wealth Advisors reported no remaining Vertex Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • TCI Wealth Advisors sold 183 Vertex Pharmaceuticals shares in Q2 2023, an estimated $57.7K.
  • TCI Wealth Advisors first reported a position in Vertex Pharmaceuticals in Q3 2015 and held it in 30 quarters.
  • TCI Wealth Advisors's Vertex Pharmaceuticals position peaked at $57.7K in Q1 2023.
  • 1,286 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2023.

Based on TCI Wealth Advisors's 13F filing for Q2 2023, filed 4 Aug 2023.